AELIS FARMA SAS EO -004
Aelis Farma SA, a clinical-stage biopharmaceutical company, focuses on discovering and developing drug candidates for the treatment of central nervous system disorders in France. The company is developing signaling-specific inhibitors of the CB1 receptors, such as AEF0117, a drug candidate, which is in Phase 2b clinical trials for the treatment of the harmful effects of excessive cannabis use; an… Read more
Market Cap & Net Worth: AELIS FARMA SAS EO -004 (69O)
AELIS FARMA SAS EO -004 (F:69O) has a market capitalization of $16.77 Million (€16.34 Million) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #32239 globally and #3592 in its home market, demonstrating a 8.60% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying AELIS FARMA SAS EO -004's stock price €1.20 by its total outstanding shares 13618098 (13.62 Million).
AELIS FARMA SAS EO -004 Market Cap History: 2022 to 2026
AELIS FARMA SAS EO -004's market capitalization history from 2022 to 2026. Data shows change from $185.36 Million to $16.77 Million (-43.72% CAGR).
AELIS FARMA SAS EO -004 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how AELIS FARMA SAS EO -004's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 69O by Market Capitalization
Companies near AELIS FARMA SAS EO -004 in the global market cap rankings as of March 19, 2026.
Key companies related to AELIS FARMA SAS EO -004 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #165 globally with a market cap of $114.33 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #285 globally with a market cap of $73.32 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #340 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #497 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #165 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $114.33 Billion | $451.59 |
| #285 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.32 Billion | $744.12 |
| #340 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #497 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
AELIS FARMA SAS EO -004 Historical Marketcap From 2022 to 2026
Between 2022 and today, AELIS FARMA SAS EO -004's market cap moved from $185.36 Million to $ 16.77 Million, with a yearly change of -43.72%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €16.77 Million | +2.56% |
| 2025 | €16.35 Million | -40.61% |
| 2024 | €27.54 Million | -85.24% |
| 2023 | €186.61 Million | +0.68% |
| 2022 | €185.36 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of AELIS FARMA SAS EO -004 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $16.77 Million USD |
| MoneyControl | $16.77 Million USD |
| MarketWatch | $16.77 Million USD |
| marketcap.company | $16.77 Million USD |
| Reuters | $16.77 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.